Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles D Blanke

Showing results (41-50 of 152) with videos related to

Pageof 16
Sort By:
The Oncologist|June 6, 2014
Effect of M1a and M1b category in metastatic colorectal cancerHagen Kennecke, Jason Yu, Sharlene Gill, et al.
JAMA Oncology|March 12, 2016
The Scientific Impact of Positive and Negative Phase 3 Cancer Clinical TrialsJoseph M Unger, William E Barlow, Scott D Ramsey, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|September 13, 2006
Outcome following surgical therapy for gastrointestinal stromal tumorsManeesh Gupta, Brett C Sheppard, Christopher L Corless, et al.
International Journal of Radiation Oncology, Biology, Physics|November 14, 2006
Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancerDong W Kim, Charles D Blanke, Huiyun Wu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 16, 2010
Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: a phase II Southwest Oncology Group Study (S0415)Philip J Gold, Bryan Goldman, Syma Iqbal, et al.
The Oncologist|November 19, 2015
S0502: A SWOG Phase III Randomized Study of Imatinib, With or Without Bevacizumab, in Patients With Untreated Metastatic or Unresectable Gastrointestinal Stromal TumorsCharles D Blanke, Cathy Rankin, Christopher Corless, et al.
Journal of the National Cancer Institute|April 24, 2018
A New Framework for Patient Engagement in Cancer Clinical Trials Cooperative Group StudiesPatricia A Deverka, Rick Bangs, Karma Kreizenbeck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumorsGeorge D Demetri, Yanfeng Wang, Elisabeth Wehrle, et al.
JAMA Network Open|May 1, 2020
Association of Patient Demographic Characteristics and Insurance Status With Survival in Cancer Randomized Clinical Trials With Positive FindingsJoseph M Unger, Charles D Blanke, Michael LeBlanc, et al.
Blood|April 9, 2004
Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinibPetri Bono, Andreas Krause, Margaret von Mehren, et al.
Pageof 16

Showing results (41-50 of 152) with videos related to

Sort By:
Pageof 16
The Oncologist|June 6, 2014
Effect of M1a and M1b category in metastatic colorectal cancerHagen Kennecke, Jason Yu, Sharlene Gill, et al.
JAMA Oncology|March 12, 2016
The Scientific Impact of Positive and Negative Phase 3 Cancer Clinical TrialsJoseph M Unger, William E Barlow, Scott D Ramsey, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|September 13, 2006
Outcome following surgical therapy for gastrointestinal stromal tumorsManeesh Gupta, Brett C Sheppard, Christopher L Corless, et al.
International Journal of Radiation Oncology, Biology, Physics|November 14, 2006
Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancerDong W Kim, Charles D Blanke, Huiyun Wu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 16, 2010
Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: a phase II Southwest Oncology Group Study (S0415)Philip J Gold, Bryan Goldman, Syma Iqbal, et al.
The Oncologist|November 19, 2015
S0502: A SWOG Phase III Randomized Study of Imatinib, With or Without Bevacizumab, in Patients With Untreated Metastatic or Unresectable Gastrointestinal Stromal TumorsCharles D Blanke, Cathy Rankin, Christopher Corless, et al.
Journal of the National Cancer Institute|April 24, 2018
A New Framework for Patient Engagement in Cancer Clinical Trials Cooperative Group StudiesPatricia A Deverka, Rick Bangs, Karma Kreizenbeck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumorsGeorge D Demetri, Yanfeng Wang, Elisabeth Wehrle, et al.
JAMA Network Open|May 1, 2020
Association of Patient Demographic Characteristics and Insurance Status With Survival in Cancer Randomized Clinical Trials With Positive FindingsJoseph M Unger, Charles D Blanke, Michael LeBlanc, et al.
Blood|April 9, 2004
Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinibPetri Bono, Andreas Krause, Margaret von Mehren, et al.
Pageof 16